semaglutide dr phillips GLP-1 drugs and muscle loss: what's the real story? | Stuart posted on the topic GLP-1 therapy in Philadelphia —

How long do the benefits last

Regional Insights North America GLP-1 Receptor Agonist Market Insights North America dominated the global GLP-1 Receptor Agonist Market in 2025 with approximately 45% of global revenues, anchored entirely by the United States' unique drug pricing environment and the commercial investment that Novo Nordisk and Eli Lilly have made in building GLP-1 prescribing across endocrinology, primary care, cardiology, and bariatric medicine

Jacobsen LV, Flint A, Olsen AK, Ingwersen SH

Solo estn financiados en terapia combinada con otros medicamentos hipoglucemiantes orales y/o insulina en pacientes con un ndice de masa corporal igual o mayor a 30 kg/m2 con diabetes mellitus tipo 2 que no logran un control glucmico

If symptoms do not resolve quickly or the patient is unable to self-treat, emergency services (999) should be contacted